Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real ‐world data from a large healthcare provider

This study aims to characterize patients initiating OPrD± RBV and assess sustained virological response (SVR). A retrospective cohort study was performed using the database of Maccabi Healthcare Services (MHS), a 2‐million‐member health plan in Israel. The study population included adults who initiated OPrD±RBV through December 2015 per health basket criteria. A gap in medication fills (>14 days between a fill's run‐out and the next fill) was used to estimate adherence. SVR was defined by the viral tests at least 12 weeks post‐treatment. The study population consisted of 403 patients (56.3% male), with a mean age of 60.7 years (SD 11.0). Overall, 71.0% were naïve to prior HCV treatment and 95.6% were treated with a 12‐week regimen. A total of 348 patients (86.4%) completed the regimen in the usual time frame (highly adherent), whereas 8.2% completed with a gap, and 4.7% purchased less than the recommended dose. SVR rates overall and among highly adherent patients were 395/403 (98.0%; 95%CI 96.1‐99.1%) and 346/348 (99.4%; 95%CI 97.9‐99.9%), respectively. GT1b patients on 12‐week regimens attained SVR rates of 194/196 (fibrosis F3) and 170/176 (cirrhosis). After a first year of provision of OPrD±RBV with good adherence, high SVR rates were achieved in various patient subgroups and comorbidities. This article is protected by copyright. All rights reserved.
Source: Journal of Viral Hepatitis - Category: Infectious Diseases Authors: Tags: Original Article Source Type: research